Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)

项目摘要/摘要 这份重新提交的报告名为“耶鲁癌症中心内科科学家高级培训计划” (YCC-ATPP)“要求为强化血液学和内科肿瘤学提供五年的支持 耶鲁医学院(YSM)/耶鲁癌症(YSM)(亚铁血红素/MedOnc)奖学金研究培训计划 中心(YCC)。我们在培训血红素/医学人方面的记录很好。我们的实习生已升入专业 在学术和临床血液学和肿瘤学环境中具有领导和成功的职位。从1987年开始， 151名研究员完成了亚铁血红素/医学联研究金方案(最初作为单独的学科；现在为 自2012年以来的联合计划)，以及在过去10年内完成该计划的72名毕业生中的46名 在学术职位上工作，其中许多是独立资助的。得到了最近对我们癌症的投资的支持 耶鲁大学和耶鲁-纽黑文医院的中心，包括增加机构承诺和 近年来的教师招聘(许多都是由同行评审资助的)，我们相信其结构和支持 由本T32提供，将使学员取得更大的成功，并将进一步增加数量 成就卓著的独立医生-科学家领袖完成我们的计划。 这款T32将建立在我们的临床培训期间建立的卓越基础上 HEME/MedOnc奖学金计划，研究员可以从该计划申请该计划。因此， 未来的实习生将已获得医学博士或医学博士学位，并完成内科 住院医师，以及两年的血红素/医学方面的临床研究员培训。这个T32程序将选择最多 来自这一群体的高度合格和多样化的候选人，希望从事癌症研究和职业生涯 已经制定了许多程序，以确保招聘、高质量的指导和留住 代表不足的少数族裔研究员。这一高级培训计划将提供优秀的导师基础， 资深和专业初级教师的转化型、临床型和基于结果的癌症研究经验 一个高度合作、协作和一体化的制度环境。该计划旨在提供 必要的财政支持，并确保为我们的研究员提供宝贵的受保护时间用于研究，允许 他们很早就确立了自己作为内科科学家的地位，并为成功地 学术生涯。按照这些思路，该计划包括职业发展规划和指导 包括在受训人员研究领域具有知识和经验的科学家和医生的委员会 在整个计划过程中提供指导。在他们的训练结束后，我们的目标是 受此T32支持的个人将发展独立运作所需的技能，包括 有能力设计、启动和完成研究项目，并有效地撰写助学金和手稿。 T32将坚定地将血红素/MedOnc研究员定位为独立的临床、转化性或基础癌症 未来的研究领导者。

PROJECT SUMMARY/ABSTRACT This resubmission titled “Yale Cancer Center Advanced Training Program for Physician-scientists (YCC-ATPP)” requests five years of support for an intensive hematology and medical oncology (Heme/MedOnc) fellowship research training program at the Yale School of Medicine (YSM)/Yale Cancer Center (YCC). Our record of training Heme/MedOnc fellows is strong. Our trainees have gone on to major positions of leadership and success in academic and clinical hematology and oncology settings. Since 1987, 151 fellows have completed the Heme/MedOnc Fellowship Program (originally as separate disciplines; now as a joint program since 2012), and 46 of the 72 graduates who completed the program within the last 10 years work in academic positions, many with independent funding. Bolstered by the recent investment in our cancer center by Yale University and Yale-New Haven Hospital, including increased institutional commitment and faculty recruitment in recent years (many with peer-reviewed funding), we believe the structure and support provided by this T32 will allow trainees to achieve even greater success and will further increase the numbers of accomplished independent physician-scientist leaders completing our program. This T32 will build on a foundation of excellence established during clinical training in our Heme/MedOnc Fellowship Program, from which fellows will be able to apply to this program. As such, the prospective trainees will have already received an MD or MD/PhD degree, completed internal medicine residency, and 2 years of clinical fellowship training in Heme/MedOnc. This T32 program will select the most highly qualified and diverse candidates from this group who wish to pursue a career in cancer research and numerous procedures have been put in place to ensure the recruitment, quality mentorship, and retention of under-represented minority fellows. This advanced training program will provide outstanding mentored basic, translational, clinical, and outcome-based cancer research experiences from senior and expert junior faculty in a highly collegial, collaborative, and integrative institutional environment. This program is designed to provide essential financial support and ensure precious protected time is given to our fellows for research, allowing them to establish themselves early on as physician-scientists, and paving the way towards a successful academic career. Along these lines, the program includes career development planning and mentorship committees including scientists and physicians with knowledge and experience in the trainee’s research field to provide guidance throughout the length of the program. At the conclusion of their training, it is our goal that individuals supported by this T32 will have developed the skills necessary to function independently, including the ability to design, initiate, and complete research projects, and to effectively write grants and manuscripts. The T32 will firmly position Heme/MedOnc fellows as independent clinical, translational, or basic cancer researcher leaders of tomorrow.